View Author
cancer patient breast tumor breast cancer methylation tissue plasminogen prognostic level therapy activator study marker analysis expression status urokinase-type plasminogen activator survival inhibitor factor treatment adjuvant model biomarker dna methylation receptor breast cancer patients tumour value protein lymph group outcome tamoxifen system urokinase table pai ‑1 prognosis node-negative urokinase-type score association upar-del result disease sample dna methylation markers base model carcinoma response grade multivariate 4/5 pitx 2 methylation assay variable pitx 2 urokinase plasminogen activator hormone microarray pai -2 prognostic value chemotherapy prognostic factors recurrence prediction rab 31 panel lymph node status plasminogen activator inhibitor cancer res schmitt hypermethylation upar-del 4/5 signi breast cancer res dataset promoter
10 Most Recent Publications
|
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
(Article)
Schmitt, M. Mengele, K. Napieralski, R. Magdolen, V. Reuning, U. Gkazepis, A. Sweep, F.C. Brünner, N. Foekens, J.A. Harbeck, N. |
2010-11-01
|
|
DNA methylation as a biomarker in breast cancer
(Article)
Martens, J.W.M. Margossian, A.L. Schmitt, M. Foekens, J.A. Harbeck, N. |
2009-12-01
|
|
DNA methylation markers predict outcome in node-positive, Estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy
(Article)
Hartmann, O. Spyratos, F. Maier, S. Plum, A. Niemann, S. Foekens, J.A. Lesche, R. Martens, J.W.M. Harbeck, N. Dietrich, D. Fassbender, A. Schmitt, M. Eppenberger-Castori, S. VincentVuaroqueaux, None Lerebours, F. Welzel, K. |
2009-01-01
|
|
Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: Identification of rab31 as an independent prognostic factor
(Article)
Kotzsch, M. Sieuwerts, A.M. Magdolen, V. Foekens, J.A. Grosser, M. Meye, A. Fuessel, S. Meijer van Gelder, M.E. Smid, M. Schmitt, M. Baretton, G. Luther, T. |
2008-09-01
|
|
The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: An immunohistochemical study
(Article)
Golouh, R. Cufer, T. Foekens, J.A. Martens, J.W.M. Sadikov, A. Nussdorfer, P. Usher, P.A. Brünner, N. Schmitt, M. Lesche, R. Maier, S. Timmermans, A.M. |
2008-07-01
|
|
DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients - Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group
(Article)
Maier, S. Nimmrich, I. Schittulli, F. Kates, R. Lesche, R. Schwope, I. Kluth, A. Marx, A. Martens, J.W.M. Foekens, J.A. Schmitt, M. Harbeck, N. Koenig, T. Eppenberger-Castori, S. Bohlmann, I. Paradiso, A. Spyratos, F. Thomssen, C. Mueller, V. Nährig, J. |
2007-07-01
|
|
European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers
(Article)
Schmitt, M. Mengele, K. Schueren, E. Sweep, F.C. Foekens, J.A. Brünner, N. Laabs, J. Malik, A. Harbeck, N. |
2007-03-01
|
|
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
(Article)
Martens, J.W.M. Nimmrich, I. Meijer van Gelder, M.E. Piepenbrock, C. Olek, A. Hofler, H. Kiechle, M. Klijn, J.G.M. Schmitt, M. Maier, S. Foekens, J.A. Koenig, T. Look, M.P. Harbeck, N. Model, F. Kluth, A. Bolt-de Vries, J. Sieuwerts, A.M. Portengen, H. |
2005-05-15
|
|
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
(Article)
Look, M.P. Kueng, W. Kates, R. Magdelenat, H. Martin, P.M. Beex, L.V. Windbichler, G. Janicke, F. Spyratos, F. Peyrat , J.P. Ricolleau, G. Cufer, T. Klijn, J.G.M. Brunner, N. Meijer van Gelder, M.E. Bendahl, P.O. Ulm, K. Schmitt, M. Eppenberger-Castori, S. Sweep, C.G. Fiets, W.E. Duggan, C. Blankenstein, M.A. Broet, P. Borstnar, S. Daxenbichler, G. Foekens, J.A. O'Higgins, N. Duffy, M.J. Daver, A. Manders, P. Romain, S. Quillien, V. Harbeck, N. Eppenberger, U. Putten, W.L.J. van Ferno, M. Christensen, I.J. Lisboa, B.W. Thomssen, C. |
2002-01-16
|
|
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
(Article)
Foekens, J.A. Henzen-Logmans, S.C. Janicke, F. Meijer van Gelder, M.E. Klijn, J.G.M. Putten, W.L.J. van Peters, H.A. Look, M.P. Portengen, H. Schmitt, M. Kramer, M.D. Brunner, N. |
2000-01-01
|
